| Oxidized form of human peroxiredoxin 5 | | homo-4-mer | 54-214 | 99.38 | |
|
| wild type human PrxV with DTT bound as a competitive inhibitor | | homo-2-mer | 54-214 | 100 | 2×D1D; 16×BR; 4×GOL; |
|
| Human peroxiredoxin 5 | | homo-2-mer | 54-214 | 100 | 2×BEZ; 10×BR; |
|
| Oxidized and reduced forms of human peroxiredoxin 5 | | homo-2-mer | 54-214 | 100 | |
|
| Oxidized and reduced forms of human peroxiredoxin 5 | | homo-2-mer | 54-214 | 100 | 2×BEZ; |
|
| HUMAN PEROXIREDOXIN 5 with a fragment | | homo-2-mer | 54-214 | 100 | 2×MCT; |
|
| Human Pdrx5 complex with a ligand BP7 | | monomer | 54-214 | 100 | 1×BP7; |
|
| HUMAN PEROXIREDOXIN 5, C47S MUTANT | | monomer | 54-214 | 99.38 | 1×BEZ; 3×CL; |
|
| Monoclinic form of human peroxiredoxin 5 | | monomer | 54-214 | 100 | 1×BEZ; |
|
| HUMAN PEROXIREDOXIN 5 with a fragment | | monomer | 54-214 | 100 | 1×EKZ; 1×DMS; |
|
| HUMAN PEROXIREDOXIN 5 | | monomer | 54-214 | 100 | 1×BEZ; |
|
| HUMAN PEROXIREDOXIN 5 with a fragment | | monomer | 54-214 | 100 | 1×CAQ; 1×DMS; |
|